Early Fulminant Leukaemia Post Autologous Bone Marrow Transplantation in Non-Hodgkin's Lymphoma Patients
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Although autologous bone marrow transplantation (ABMT) is a curative option for about 50% of the patients with progressive or relapsing lymphomas, considerable concern has been raised recently over the emerging rates of secondary malignancies following ABMT. A 15% cumulative incidence of myelodysplasia 5 years after BMT is of major concern. We hereby describe a unique form of leukaemia occurring 4-6 weeks post ABMT for non-Hodgkin's lymphoma patients. The possible etiology for this phenomenon as well as its relation to the classical MDS post ABMT is discussed.
References
1.
Stone R
. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress. Blood. 1994; 83(12):3437-40.
View
2.
Mouratidou M, Sotiropoulos D, Deremitzaki K, Spathas D, Hoffbrand A, Prentice H
. Recurrence of acute leukemia in donor cells after bone marrow transplantation: documentation by in situ DNA hybridization. Bone Marrow Transplant. 1993; 12(1):77-80.
View
3.
Miller J, Arthur D, Litz C, Neglia J, MILLER W, Weisdorf D
. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994; 83(12):3780-6.
View
4.
Travis L, Curtis R, Stovall M, Holowaty E, van Leeuwen F, Glimelius B
. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1994; 86(19):1450-7.
DOI: 10.1093/jnci/86.19.1450.
View
5.
Weisdorf D, Haake R, MILLER W, McGlave P, LeBien T, Vallera D
. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotype and in vitro purging. Bone Marrow Transplant. 1991; 8(2):135-42.
View